NIH Locks Doors on Cancer and Heart Grant Reviews for January Secrecy Spree
Published Date: 12/9/2025
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in early January 2026 to review and decide on important grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for cancer, heart, and neuroscience research. Scientists and small businesses applying for grants should watch these dates closely as they impact who gets money to fuel new discoveries.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Small‑Business Grant Panels in January
The NIH Center for Scientific Review will hold closed virtual panels that review Small Business grant applications on January 8, 2026 (Cardiovascular Biology and Hematology) and January 29, 2026 (Cancer Therapeutics). If you are a small business applying for these NIH grants, those meetings are when reviewers evaluate applications and decide who receives funding.
Research & Fellowship Reviews in January
The NIH Center for Scientific Review will hold closed virtual meetings on January 7-8, 2026 (Cancer Center Support Grants), January 9, 2026 (Fellowships: Clinical Neuroscience), January 14, 2026 (Musculoskeletal Sciences), January 21, 2026 (HIV molecular virology and related topics), and January 29, 2026 (Health Services, Clinical Informatics, and Digital Health) to review and evaluate grant and fellowship applications. If you are a scientist, trainee, or institution that applied to these programs, these are the dates when reviewers evaluate applications and funding decisions are made.
Meetings Closed to Protect Trade Secrets
The meetings listed are closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, commercial property (including patentable material), and personal information; the notice says disclosure would be a clearly unwarranted invasion of personal privacy. This protects applicants' proprietary and personal information during the January 2026 reviews.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-22292, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on January 27, 2026, to review important grant applications about liver health and toxicology. These meetings keep sensitive info private to protect personal and commercial secrets. Scientists and researchers applying for grants should note this date, but no new funding changes or costs are announced.
Next: 2025-22294, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding a closed virtual meeting on February 5, 2026, to review grant applications about aging biology. These meetings are private to protect secret research ideas and personal info. Scientists applying for grants and the NIH are the main players, with no new costs or deadlines announced.